Concepedia
Statistics
Publications
15
Citations
861
H-Index
14
Active since
2014
Affiliations
Washington University in St. Louis(Current)
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Dana-Farber Brigham Cancer Center
James S. McDonnell Foundation
Paul Zolkind is an author at Washington University in St. Louis specializing in surgical oncology, surgery, and clinical trials.
Top concepts
HealthSurgeryMedicineOncologyPathologyImmunologyImmunotherapyCancer TherapyClinical TrialsSurgical Oncology
Publications per year
2014–2024
Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus–Unrelated Head and Neck Cancer: A Multicenter, Phase II Trial
Ravindra Uppaluri, Katie M. Campbell, Ann Marie Egloff et al. · Clinical Cancer Research · 2020 · 342 citations · Full text
Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen–Specific T Cells
Jay Friedman, Ellen Moore, Paul Zolkind et al. · Clinical Cancer Research · 2019 · 78 citations · Full text
Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HNSCC).
Ravindra Uppaluri, Paul Zolkind, Tianxiang Lin et al. · Journal of Clinical Oncology · 2017 · 77 citations
Surgical Oncology, Pathologic Treatment Effect, Immunology +20
Biomarker and Tumor Responses of Oral Cavity Squamous Cell Carcinoma to Trametinib: A Phase II Neoadjuvant Window-of-Opportunity Clinical Trial
Ravindra Uppaluri, Ashley E. Winkler, Tianxiang Lin et al. · Clinical Cancer Research · 2016 · 52 citations · Full text
Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders
Liye Zhou, Zexian Zeng, Ann Marie Egloff et al. · Journal for ImmunoTherapy of Cancer · 2022 · 47 citations · Full text
1–5 of 15